This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Daiichi Sankyo Co., Ltd.
Drug Names(s): AC430
AC410 is a potent, selective, orally-administered, small molecule inhibitor of JAK2.
Ambit was initially developing the JAK2 inhibitor, AC430, a racemic mixture (50/50) of two enantiomers (mirror images), AC410 and AC409. Following a Phase I clinical trial of AC430 in healthy volunteers, Ambit selected AC410 over AC430 based on its superior pharmacokinetics. The FDA has indicated that Ambit can continue the clinical development of AC410 under the IND for AC430 without a need to repeat preclinical toxicology studies completed with AC430, contingent on review by the FDA of the manufacturing process for AC410.
Ambit and Daiichi
In Setpember 2014, Daiichi Sankyo and Ambit Biosciences announced that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis. In addition to the upfront cash payment, each Ambit Biosciences stockholder will receive one Contingent Value Right (CVR), entitling the holder to receive an additional cash payment of up to $4.50 for each share they own if certain commercialization related milestones are achieved. The total transaction is valued at up to $410 million on a fully diluted basis.
In November 2014, Daiichi Sankyo and Ambit Biosciences announced that, as of the expiration of the tender offer, a total of 15,674,238 shares of Ambit Biosciences common stock had been validly tendered and not...See full deal structure in Biomedtracker
Additional information available to subscribers only: